Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 18/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumagillin SCHEMBL13819097 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL8130 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL18517986 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL17959149 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL12526078 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL18517793 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL15263951 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL6953272 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL15745869 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 | |
| Fumagillin SCHEMBL18517985 | 1.00 | METAP2 (1.00) | METAP2ABCB11LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782489-B2 | MetAP-2 inhibitor polymersomes for therapeutic administration | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782489-B2 | MetAP-2 inhibitor polymersomes for therapeutic administration | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160361428-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-12-15 | — | — | US | disclosed |
| US-9446140-B2 | MetAP-2 inhibitor polymersomes for therapeutic administration | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160136292-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-05-19 | — | — | US | disclosed |
| US-9272050-B2 | MetAP-2 inhibitor polymersomes for therapeutic administration | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150104406-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-04-16 | — | — | US | disclosed |
| US-8865151-B2 | MetAP-2 inhibitor polymersomes for therapeutic administration | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140301969-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-09 | — | — | US | disclosed |
| US-8790634-B2 | MetAP-2 inhibitor polymersomes for therapeutic administration | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-29 | — | — | US | disclosed |
| US-20100158855-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100111894-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104406-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | METAP2, PHLPP2, METAP1 | METAP2 1/4885ABCB11 192/4885LMNA 4396/4885 |
| US-20100111894-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | METAP2, PHLPP2, METAP1 | METAP2 1/4885ABCB11 192/4885LMNA 4396/4885 |
| US-20140301969-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | METAP2, LCP2, FAM222B | METAP2 1/4885ABCB11 1539/4885LMNA 4343/4885 |
| US-20160361428-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | METAP2, LCP2, FAM222B | METAP2 1/4885ABCB11 1539/4885LMNA 4343/4885 |
| US-20160136292-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | METAP2, PHLPP2, METAP1 | METAP2 1/4885ABCB11 192/4885LMNA 4396/4885 |
| US-20100158855-A1 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION | METAP2, LCP2, FAM222B | METAP2 1/4885ABCB11 1539/4885LMNA 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.